Skip to main content
. 2021 May 24;8:651600. doi: 10.3389/fmed.2021.651600

Figure 3.

Figure 3

EBLN3P promotes CRC tumor growth in vivo. (A) Representative images of the subcutaneous tumors formed by EBLN3P-knockdown and control SW480 cells. (B) Tumor volumes were detected every 7 days. (C) The subcutaneous tumor weights were detected at the 28th day after injection. **p < 0.01.